{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-017178","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.662407+00:00","generated_at":"2026-05-26T03:29:32.388128+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cognition Therapeutics passes Phase 2 futility analysis for zervimesine in geographic atrophy","bullets":["Oral zervimesine (CT1812) passed futility analysis in Phase 2 GA trial; treated patients experienced slower lesion growth vs placebo.","MAGNIFY study enrolled 100 participants; final visits completed Feb 2025; full unblinded results expected Q2 2025.","Company concluding study early to preserve capital; plans to pursue indications in Alzheimer's and DLB.","Prior Phase 2 SHIMMER (DLB) showed 86% improvement on NPI; SHINE (Alzheimer's) showed 95% cognitive decline reduction in biomarker subgroup."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-017178","json":"https://secwatch.observer/filing/0001104659-25-017178.json","markdown":"https://secwatch.observer/filing/0001104659-25-017178.md","text":"https://secwatch.observer/filing/0001104659-25-017178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925017178/0001104659-25-017178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925017178/tm257579d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:29:32.388128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}